Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retroviruses02:33

Retroviruses

14.6K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
14.6K
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

49.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Rethinking viral vector quantification: a microfluidic approach to standardised functional titre assays.

Frontiers in bioengineering and biotechnology·2026
Same author

Membrane adsorber design for lentiviral vector recovery.

Molecular therapy. Methods & clinical development·2025
Same author

In-line circular dichroism and fluorescence for real-time monitoring of monoclonal antibody structure during affinity chromatography.

Journal of chromatography. A·2025
Same author

Enhancing titers of therapeutic lentiviral vectors using PKC agonists.

Molecular therapy. Methods & clinical development·2025
Same author

Gender difference in pre-clinical liver-directed gene therapy with lentiviral vectors.

Experimental biology and medicine (Maywood, N.J.)·2025

Related Experiment Video

Updated: Jan 14, 2026

A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
10:42

A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells

Published on: December 12, 2017

16.1K

Risks of replication-competent retro/lentivirus from associated vector systems: Is it time for a roadmap toward

Daniel Farley1, Samuel Stockdale1, Charles Moore-Kelly1

  • 1OXB (Oxford Biomedica), Windrush Court, Transport Way, Oxford OX4 6LT, UK.

Molecular Therapy. Methods & Clinical Development
|October 27, 2025
PubMed
Summary

Third-generation retroviral and lentiviral vectors (RV/LVs) possess high safety. A minimal-path model suggests the risk of generating replication-competent retroviruses (RCRs) or replication-competent lentiviruses (RCLs) is very low in current systems.

Keywords:
CMCRCLRCRbatch-releasegene therapylentiviral vectorsrecombinationregulatory agenciesreplication-competent retrovirus/lentivirusretroviral vectorssafety testing

More Related Videos

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

36.1K
Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System
08:46

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

36.8K

Related Experiment Videos

Last Updated: Jan 14, 2026

A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells
10:42

A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells

Published on: December 12, 2017

16.1K
Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
11:08

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

36.1K
Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System
08:46

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

36.8K

Area of Science:

  • Gene therapy vector development
  • Molecular virology
  • Biotechnology safety

Background:

  • Third-generation retroviral and lentiviral vectors (RV/LVs) offer improved safety profiles.
  • Updated regulatory guidance exists for replication-competent retrovirus (RCR) and replication-competent lentivirus (RCL) assays.
  • A reassessment of RCR/RCL formation risk in RV/LV systems is needed.

Purpose of the Study:

  • To review the historical context of RCR formation and safety features in RV/LV systems.
  • To model the risk of RCL formation in four-component LV systems using established recombination rates.
  • To propose a roadmap for reduced RCR/RCL testing based on current vector system safety.

Main Methods:

  • Review of historical RCR generation and third-generation RV/LV safety features.
  • Development of a minimal-path model for RCL formation in four-component LV systems.
  • Analysis of recombination rates between plasmid DNA and retroviral RNA.

Main Results:

  • The probability of generating a single RCL genome molecule at a 200-L scale is less than 1 in 10,000 per bioreactor.
  • Using packaging cell lines with integrated vector components reduces RCL formation probability by 100-fold.
  • Contemporary RV/LV systems demonstrate a low probability of RCR/RCL generation.

Conclusions:

  • The low improbability of RCR/RCL generation in current RV/LV systems supports a move towards reduced testing.
  • Consideration of a roadmap for reduced testing and assay development unification is recommended.
  • Further contemplation on aspects of a reduced testing roadmap is encouraged for the field.